Key result
Chronic treatment with ORM-11035 significantly reduced LVEDP (9 vs 14 mmHg, P=0.0002) and BNP levels without lowering systolic blood pressure in a rat model of HFpEF.
Why the study?
Heart failure with preserved ejection fraction is increasingly common, but there is currently no established pharmacological therapy.
Does ORM-11035 improve cardiac function and remodelling in a rat model of cardiorenal HFpEF?
Does ORM-11035 improve cardiac function and remodelling in a rat model of cardiorenal HFpEF?
Absolute Event Rate: 9% vs 14%
p-value: p=0.0002
Chronic inhibition of the Na+/Ca2+ exchanger with ORM-11035 attenuated cardiac remodelling and diastolic dysfunction without lowering systemic blood pressure in a rat model of HFpEF.
Does not support clinical use in HFpEF; leaves open translation of ORM-11035 effects from rat models to patients.
Aims Heart failure with preserved ejection fraction (HFpEF) is increasingly common but there is currently no established pharmacological therapy. We hypothesized that ORM-11035, a novel specific Na+/Ca2+ exchanger (NCX) inhibitor, improves cardiac function and remodelling independent of effects on arterial blood pressure in a model of cardiorenal HFpEF. Methods and results Rats were subjected to subtotal nephrectomy (NXT) or sham operation. Eight weeks after intervention, treatment for 16 weeks with ORM-11035 (1 mg/kg body weight) or vehicle was initiated. At 24 weeks, blood pressure measurements, echocardiography and pressure–volume loops were performed. Contractile function, Ca2+ transients and NCX-mediated Ca2+ extrusion were measured in isolated ventricular cardiomyocytes. NXT rats (untreated) showed a HFpEF phenotype with left ventricular (LV) hypertrophy, LV end-diastolic pressure (LVEDP) elevation, increased brain natriuretic peptide (BNP) levels, preserved ejection fraction and pulmonary congestion. In cardiomyocytes from untreated NXT rats, early relaxation was prolonged and NCX-mediated Ca2+ extrusion was decreased. Chronic treatment with ORM-11035 significantly reduced LV hypertrophy and cardiac remodelling without lowering systolic blood pressure. LVEDP [14 ± 3 vs. 9 ± 2 mmHg; NXT (n = 12) vs. NXT + ORM (n = 12); P = 0.0002] and BNP levels [71 ± 12 vs. 49 ± 11 pg/mL; NXT (n = 12) vs. NXT + ORM (n = 12); P < 0.0001] were reduced after ORM treatment. LV cardiomyocytes from ORM-treated rats showed improved active relaxation and diastolic cytosolic Ca2+ decay as well as restored NCX-mediated Ca2+ removal, indicating NCX modulation with ORM-11035 as a promising target in the treatment of HFpEF. Conclusion Chronic inhibition of NCX with ORM-11035 significantly attenuated cardiac remodelling and diastolic dysfunction without lowering systemic blood pressure in this model of HFpEF. Therefore, long-term treatment with selective NCX inhibitors such as ORM-11035 should be evaluated further in the treatment of heart failure.
No takes yet. Share an insight, caveat, or question.
Primeßnig et al. (2019) studied Heart failure with preserved ejection fraction (HFpEF) (n=24). ORM-11035 vs. vehicle was evaluated on Left ventricular end-diastolic pressure (LVEDP) (p=0.0002). Chronic treatment with ORM-11035 significantly reduced LVEDP (9 vs 14 mmHg, P=0.0002) and BNP levels without lowering systolic blood pressure in a rat model of HFpEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: